Pharmacodynamics of telithromycin In vitro against respiratory tract pathogens. - Wikidata - wikimedia - TriplyDB

Pharmacodynamics of telithromycin In vitro against respiratory tract pathogens.

Pharmacodynamics of telithromycin In vitro against respiratory tract pathogens.

http://www.wikidata.org/entity/Q33981093

about

Pharmacodynamic profile of telithromycin against macrolide- and fluoroquinolone-resistant Streptococcus pneumoniae in a neutropenic mouse thigh model CEM-101 activity against Gram-positive organisms.Telithromycin: an oral ketolide for respiratory infections.Ketolides in the treatment of respiratory infections.Postantibiotic effect of disinfection treatment by photolysis of hydrogen peroxide.Dead bugs don't mutate: susceptibility issues in the emergence of bacterial resistance.In vitro anti-listerial activities of crude n-hexane and aqueous extracts of Garcinia kola (heckel) seeds.Biocidal effects of stem bark extract of Chrysophyllum albidium G. Don on vancomycin-resistant Staphylococcus aureus.Telithromycin in the treatment of acute bacterial sinusitis, acute exacerbations of chronic bronchitis, and community-acquired pneumonia Pharmacodynamic functions: a multiparameter approach to the design of antibiotic treatment regimens.Postantibiotic effects of ABT-773 and amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae.Ketolide antimicrobial activity persists after disruption of interactions with domain II of 23S rRNA.Pharmacodynamic activity of telithromycin at simulated clinically achievable free-drug concentrations in serum and epithelial lining fluid against efflux (mefE)-producing macrolide-resistant Streptococcus pneumoniae for which telithromycin MICs vary Stem bark extract and fraction of Persea americana (Mill.) exhibits bactericidal activities against strains of bacillus cereus associated with food poisoning.In vitro antilisterial properties of crude methanol extracts of Garcinia kola (Heckel) seeds.

P2860

Q33555366-C1830B9C-22B4-4D93-AA8F-E0546C3946AF Q34100146-5F8B0550-ECCF-4C6D-926B-CA21ACADBD35 Q34401542-E265D67D-EECE-4BFA-A81A-FBDC4FF75BA1 Q34544732-CCFF7A88-2E92-47CB-8E37-E93B89130C17 Q35007552-5ACE61CB-9E8B-4A1C-B542-F03418674878 Q35047705-9F45929D-FD48-4876-8E04-84B1C7F4DC98 Q35536073-7B28A214-6CF3-4310-BA9B-ED08E7D72AB7 Q35966573-20AA337D-A6FE-4D86-BFA4-412469858E2A Q37116814-6C38B49C-4E7E-4783-BF88-DDE011B0BA44 Q37568933-F0C200EA-24C9-4127-A965-CADD926FF3D1 Q39479282-73091B1D-776F-495F-BCE1-ABE7820166A4 Q40165104-D842A955-5CC6-4F53-AFEE-6FEF2597B273 Q42252396-5B40314B-DDDD-44A5-B025-876761BCBBCB Q52656337-A031A7B2-D0AD-4A9E-A180-546F15B4A8EB Q55031628-1AA1359D-E78B-4912-825C-648E4386F197

P2860

Pharmacodynamics of telithromycin In vitro against respiratory tract pathogens.

http://www.wikidata.org/entity/Q33981093

description

2001 nî lūn-bûn

@nan

2001 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2001 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2001年の論文

@ja

2001年論文

@yue

2001年論文

@zh-hant

2001年論文

@zh-hk

2001年論文

@zh-mo

2001年論文

@zh-tw

2001年论文

@wuu

name

Pharmacodynamics of telithromycin In vitro against respiratory tract pathogens.

@ast

Pharmacodynamics of telithromycin In vitro against respiratory tract pathogens.

@en

type

label

Pharmacodynamics of telithromycin In vitro against respiratory tract pathogens.

@ast

Pharmacodynamics of telithromycin In vitro against respiratory tract pathogens.

@en

prefLabel

Pharmacodynamics of telithromycin In vitro against respiratory tract pathogens.

@ast

Pharmacodynamics of telithromycin In vitro against respiratory tract pathogens.

@en

P1433

Q33981093-34A96109-E42C-4D51-8007-79BB0E7C6E31

P1476

Q33981093-44987F35-488F-4122-9046-F8B7309C1146

P2093

Q33981093-36FD8148-EC0A-4298-A7BD-54F9D5FABEEC

Q33981093-7EFA33BC-9CAF-45D6-BB5F-598D366A7AC2

Q33981093-D447DC12-35E9-4E7E-B14C-B61BB4B6E54C

P2860

Q33981093-0B1128B8-4ABD-46F1-A30A-79F0D8C2EC0E

Q33981093-3B03C459-F1A6-4F79-A984-ED78ACD1BB9B

Q33981093-4DA4A5A9-53B1-4BA1-85D8-1132C6C4ED1D

Q33981093-53869FC5-AE81-41FD-9F7C-97EB8331F911

Q33981093-6BD4F08B-A672-46A9-AE68-1ABE7AFE7210

Q33981093-90CC86D4-9DD0-4976-9054-AECB9923792F

Q33981093-A751CF76-7BC4-4482-BE4A-1603706D1CFC

Q33981093-AC06E467-B877-4B38-B3F6-E18C13835AB6

Q33981093-BAD48949-2499-4623-946F-3CB65E5DAD5E

Q33981093-C0D24DB0-7C91-4348-978F-B12169E2C8F7

P304

Q33981093-D15FB365-C49F-4614-8418-806DC7FBC735

P31

Q33981093-5B3D8AA3-36D2-44E9-9BB6-71E2A3BFCD40

P356

Q33981093-31512424-D994-4609-B085-F2FE11FA483E

P407

Q33981093-055C2FA7-6159-4437-817A-567916D02103

P433

Q33981093-CA811481-F60B-4293-A1AB-15131E4E863B

P478

Q33981093-7C9F107D-6614-4505-BE47-DF2410BD5637

P577

Q33981093-1E494B45-D9F1-424D-92B4-3DB892B2765C

P5875

Q33981093-C83CDDF4-251E-435D-82E9-FA537BB33DD0

P698

Q33981093-78FC819A-7F4C-429D-8B9B-A2E63471D47F

P932

Q33981093-798FBD11-8D78-4C2F-BA4E-9EEEFBFD23CB

P356

AAC.45.1.23-29.2001

P1433

Antimicrobial Agents and Chemotherapy

P1476

Pharmacodynamics of telithromycin In vitro against respiratory tract pathogens.

@en

P2093

E Löwdin

http://www.w3.org/2001/XMLSchema#string

I Odenholt

http://www.w3.org/2001/XMLSchema#string

O Cars

http://www.w3.org/2001/XMLSchema#string

P2860

Susceptibilities of penicillin- and erythromycin-susceptible and -resistant pneumococci to HMR 3647 (RU 66647), a new ketolide, compared with susceptibilities to 17 other agents

Antipneumococcal activities of a ketolide (HMR 3647), a streptogramin (quinupristin-dalfopristin), a macrolide (erythromycin), and a lincosamide (clindamycin).

In vitro activities of the new ketolide antibiotics HMR 3004 and HMR 3647 against Streptococcus pneumoniae in Germany.

In vitro activities of the ketolide HMR 3647 against recent gram-positive clinical isolates and Haemophilus influenzae.

Ketolide treatment of Haemophilus influenzae experimental pneumonia

In vitro activities of two ketolides, HMR 3647 and HMR 3004, against gram-positive bacteria

Pharmacodynamic effects of sub-MICs of benzylpenicillin against Streptococcus pyogenes in a newly developed in vitro kinetic model.

The in-vitro activity of HMR 3647, a new ketolide antimicrobial agent.

Postantibiotic effects and postantibiotic sub-MIC effects of roxithromycin, clarithromycin, and azithromycin on respiratory tract pathogens.

Pharmacodynamic effects of subinhibitory concentrations of beta-lactam antibiotics in vitro.

P304

23-29

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.45.1.23-29.2001

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

45

http://www.w3.org/2001/XMLSchema#string

P577

2001-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

12207632

http://www.w3.org/2001/XMLSchema#string

P698

11120939

http://www.w3.org/2001/XMLSchema#string

P932

90234

http://www.w3.org/2001/XMLSchema#string